ClinicalTrials.gg
RecruitingNCT06166654DRAIN-AHFUpdated Oct 27, 2026

Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload

A Phase 3 interventional study of Acetazolamide and Metolazone 2.5 MG in Acute Heart Failure, sponsored by Johannes Grand. Recruiting at 6 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Johannes Grand · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 26, 2026Site recruiting status changedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
939
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing acetazolamide in Heart Failure — 6 open to participants now, 7 under way, 2 of them phase 3. Acetazolamide · Heart Failure.

Planned enrollment
2nd of 14
939 · median 66
Started
2024
with 3 others
Phase 3
3 of 14
2 open now
Registered
8th of 14
by date
Lead sponsor
1 of 14
Johannes Grand

Among the 14 studies testing acetazolamide in Heart Failure, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2024, is one of 3 in phase 3, and was the 8th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 14 studies testing acetazolamide in Heart Failure are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About acetazolamide

Acetazolamide: first FDA approval 1953 (DIAMOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing acetazolamide in Heart Failure, or all of them as a file.
02

Study summary

This trial aims to identify the best strategy for treating acute heart failure (AHF) with volume overload in patients at risk of diuretic resistance. It is a double-blinded, randomized, controlled, multicenter study comparing loop-diuretics combined with metolazone, loop-diuretics combined with acetazolamide, and loop-diuretics with matching placebos.

Eligible participants are adults aged 18 years or older who are hospitalized with AHF and have clinical signs of congestion and a risk of diuretic resistance.

The primary outcome is the number of days alive and out of hospital through day 30. Secondary outcomes are clinical benefit at 30 days, assessed using a hierarchical win ratio; days alive and out of hospital through day 90; and the duration of the index hospital admission.

The trial aims to enroll 939 participants across three treatment arms (313 per arm). The sample size is based on detecting a clinically relevant between-group difference of two days alive and out of hospital through day 30, with 80% power and adjustment for comparisons between the three groups.

Read the detailed description

Intravenous loop diuretics remain the cornerstone of treatment for acute heart failure with volume overload. However, a substantial proportion of patients experience an insufficient diuretic response, which may contribute to persistent congestion, prolonged hospitalization, and adverse clinical outcomes. Diuretic resistance may arise from several mechanisms, including reduced delivery of diuretics to their site of action, impaired renal function, and compensatory sodium reabsorption in nephron segments not targeted by loop diuretics.

Sequential nephron blockade represents a potential strategy to overcome diuretic resistance by combining diuretics acting at different sites of the nephron. Acetazolamide inhibits carbonic anhydrase in the proximal tubule, thereby reducing proximal sodium bicarbonate reabsorption and increasing sodium delivery to downstream nephron segments. Metolazone is a thiazide-like diuretic that inhibits sodium-chloride cotransport in the distal convoluted tubule, potentially counteracting compensatory distal sodium reabsorption during loop diuretic treatment.

Although both approaches may enhance natriuresis and facilitate decongestion, they differ in their mechanisms of action, electrolyte effects, and potential adverse events. Direct randomized comparisons of these strategies in patients hospitalized with acute heart failure are limited, and uncertainty remains regarding their relative clinical effectiveness and safety.

This trial is designed to address this evidence gap by directly comparing proximal and distal tubular diuretic strategies as adjuncts to intravenous loop diuretic therapy. The findings may help establish the optimal pharmacological approach to decongestion in patients with acute heart failure who are at risk of diuretic resistance.

03

Conditions studied

  • Acute Heart Failure

Browse trials for

Keywords

  • acute heart failure
  • decongestion
  • diuretic
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Acute hospital admission with a clinical diagnosis of acute heart failure with volume overload.
  3. Display risk of diuretic resistance, characterized by:

    1. Daily loop-diuretics administration for a minimum of 7 days before admission, or
    2. Insufficient decongestion observed in the preceding 24 hours (weight reduction \<500g or negative fluid balance \<1L) despite being treated with high-dose IV loop diuretic (equivalent to ≥120 mg IV furosemide within 24 hours).
  4. Clinical signs of congestion, indicated by one or more of the following: pitting peripheral edema, ascites, elevated jugular venous pressure, or radiological/ultrasonic evidence of pulmonary congestion.

Exclusion criteria

Exclusion Criteria:

  1. Acute coronary syndrome
  2. Systolic blood pressure \<85 mmHg
  3. Use of renal replacement therapy or ultrafiltration in-hospital before study inclusion
  4. Treatment with acetazolamide or metolazone during the index hospitalization prior to randomization
  5. Known allergy to any of the used drugs
  6. Severe hypokalemia (\<2.5 mmol/l) or severe hyponatremia (\<125 mmol/l)
  7. Severe hepatic impairment defined as an >1.5 (not due to anticoagulant therapy) and/or a score ≥B7
  8. Known pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
939 participants (estimated)

Study arms

  • Active comparator
    Acetazolamide

    Acetazolamide 500 mg IV at randomization (day 0) and on the next three mornings (days 1, 2 and 3), with a matching placebo-metolazone tablet at each administration. The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.

    Drug: Acetazolamide

  • Active comparator
    Metolazone

    Metolazone 2.5 mg orally at randomization (day 0) and on the next three mornings (days 1, 2 and 3), with a matching placebo-acetazolamide injection at each administration. The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.

    Drug: Metolazone 2.5 MG

  • Placebo comparator
    Placebo

    Matching placebo-acetazolamide injection and placebo-metolazone tablet at randomization (day 0) and on the next three mornings (days 1, 2 and 3), in addition to usual care with loop-diuretics (SGLT2 inhibitors are allowed). The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.

    Other: Double-placebo

Interventions

  • Acetazolamide 500 mg IV at randomization (day 0) and on the next three mornings (days 1, 2 and 3), with a matching placebo-metolazone tablet at each administration. The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.

  • DrugMetolazoneStudies of MetolazoneMetolazone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Metolazone 2.5 mg orally at randomization (day 0) and on the next three mornings (days 1, 2 and 3), with a matching placebo-acetazolamide injection at each administration. The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.

  • OtherDouble-placebo

    Matching placebo-acetazolamide injection and placebo-metolazone tablet at randomization (day 0) and on the next three mornings (days 1, 2 and 3), in addition to usual care with loop-diuretics (SGLT2 inhibitors are allowed). The intervention phase does not exceed 72 hours and is stopped earlier at complete decongestion, discharge, or protocol-defined stopping criteria. Loop-diuretic treatment follows clinical assessment and current guidelines.

06

What researchers measure

Primary outcomes

  1. Days alive and out of hospital through day 30

    Number of days alive and out of hospital during the 30-day period from inclusion. A return visit to the emergency department with discharge on the same day counts as one day in hospital.

    Time frame: 30 days

Secondary outcomes

  1. Clinical benefit at 30 days assessed using a hierarchical win ratio

    Clinical benefit at 30 days, consisting of all-cause death, readmission after discharge from the index hospitalization, new receipt of renal replacement therapy, or persistent renal dysfunction (final inpatient creatinine ≥200% of baseline), assessed using a hierarchical win-ratio approach.

    Time frame: 30 days

  2. Days alive and out of hospital through day 90

    Number of days alive and out of hospital from inclusion through day 90.

    Time frame: 90 days

  3. Duration of the index hospital admission

    Number of days admitted during the index hospital admission.

    Time frame: From index hospital admission until discharge, assessed up to 90 days

07

Study locations

5 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Mar 2028, 41 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 41 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2027 → Mar 2028 and completion Dec 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2023
First posted
Dec 12, 2023
StartActual
Sep 5, 2024
Primary completionEst.
Mar 2, 2028was Dec 2027
CompletionEst.
May 1, 2028was Dec 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed. Bispebjerg Hospital is now Recruiting
Show 3 added (3 Denmark)
  • Aarhus University Hospital · Aarhus N, Denmark
  • Herlev Hospital · Herlev, Denmark
  • Odense University Hospital · Odense C, Denmark
Show 2 removed
  • Aarhus university Hospital · Aarhus, Denmark
  • Herlev-Gentofte hospital · Copenhagen, Denmark
Oct 26, 2026
Primary completion
Dec 30, 2027→Mar 2, 2028
Oct 26, 2026
Study completion
Dec 30, 2027→May 1, 2028
Oct 26, 2026
Eligibility
1 exclusion criterion added, 1 removed
What changed in the criteria
Exclusion criteria
  • RemovedSevere hepatic impairment or liver cirrhosis
  • AddedSevere hepatic impairment defined as an INR >1.5 (not due to anticoagulant therapy) and/or a Child-Pugh score ≥B7
Oct 26, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedDays alive and out- of- hospital tothrough day 30Time frame: 30 days
Oct 26, 2026
Secondary outcomes
3 added, 3 removed
What changed in the outcomes
  • AddedClinical benefit at 30 days assessed using a hierarchical win ratioTime frame: 30 days
  • AddedDays alive and out of hospital through day 90Time frame: 90 days
  • AddedDuration of the index hospital admissionTime frame: From index hospital admission until discharge, assessed up to 90 days
  • RemovedWin ratio of 1. all-cause death, 2. Readmisison, 3. renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value), assessed using a Hierarchical win-ratio' approach.Time frame: 30 days
  • RemovedKansas City Cardiomyopathy QuestionnaireTime frame: 30 days
  • RemovedDecongestion score 72 hours after inclusionTime frame: 72 hours
Oct 26, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Amager-Hvidovre Hospital · Hvidovre, DenmarkContact person changed (no phone or email listed)
  • Bispebjerg Hospital · Copenhagen, DenmarkContact •••3767→•••3767
  • Zealand University Hospital · Roskilde, DenmarkContact person changed (no phone or email listed)
Oct 26, 2026
Design
Phase 4→Phase 3
Oct 26, 2026
Show all 2 updates
  1. Oct 27, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 26, 2026
    3 sites added, 2 sites removed. Bispebjerg Hospital is now Recruiting
    Show 3 added (3 Denmark)
    • Aarhus University Hospital · Aarhus N, Denmark
    • Herlev Hospital · Herlev, Denmark
    • Odense University Hospital · Odense C, Denmark
    Show 2 removed
    • Aarhus university Hospital · Aarhus, Denmark
    • Herlev-Gentofte hospital · Copenhagen, Denmark
    Primary completion Dec 30, 2027→Mar 2, 2028
    Study completion Dec 30, 2027→May 1, 2028
    Eligibility 1 exclusion criterion added, 1 removed
    What changed in the criteria
    Exclusion criteria
    • RemovedSevere hepatic impairment or liver cirrhosis
    • AddedSevere hepatic impairment defined as an INR >1.5 (not due to anticoagulant therapy) and/or a Child-Pugh score ≥B7
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedDays alive and out- of- hospital tothrough day 30Time frame: 30 days
    Secondary outcomes 3 added, 3 removed
    What changed in the outcomes
    • AddedClinical benefit at 30 days assessed using a hierarchical win ratioTime frame: 30 days
    • AddedDays alive and out of hospital through day 90Time frame: 90 days
    • AddedDuration of the index hospital admissionTime frame: From index hospital admission until discharge, assessed up to 90 days
    • RemovedWin ratio of 1. all-cause death, 2. Readmisison, 3. renal-replacement therapy, or persistent renal dysfunction (defined as a final inpatient creatinine value ≥200% of the baseline value), assessed using a Hierarchical win-ratio' approach.Time frame: 30 days
    • RemovedKansas City Cardiomyopathy QuestionnaireTime frame: 30 days
    • RemovedDecongestion score 72 hours after inclusionTime frame: 72 hours
    Design Phase 4→Phase 3
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Amager-Hvidovre Hospital · Hvidovre, DenmarkContact person changed (no phone or email listed)
    • Bispebjerg Hospital · Copenhagen, DenmarkContact •••3767→•••3767
    • Zealand University Hospital · Roskilde, DenmarkContact person changed (no phone or email listed)
    + 4 other changes: identifiers, verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06166654
Lead sponsor
Johannes Grand
Responsible party
Johannes Grand (Principal Investigator, Copenhagen University Hospital, Hvidovre) — Sponsor-investigator
First posted
Dec 12, 2023
Start date
Sep 5, 2024
Primary completion
Mar 2, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Johannes Grand, MD, Phd, MPH
Contact
johannes.grand@regionh.dk
+4535452121
Sandra Tonning, MD
Contact
Johannes Grand, MD, Phd, MPH
principal investigator · Amager-Hvidovre Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetazolamide · Metolazone

Start the discussion